Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Mediation between Bayer and plaintiffs in the United States aims to clarify all justified claims related to Roundup herbicide both at the national and state level, mediator Ken Feinberg told a German magazine.

Mediation between Bayer, plaintiffs seeks to clarify all justified claims: U.S. mediator

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q3 2019 Results - Earnings Call Transcript

Bayer's (BAYRY) earnings beat and revenues rise on the back of growth across all reported segments in the third quarter. The company updates guidance to include impact of discontinued operations.

Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Rise Y/Y

Bayer , the world's largest maker of seeds and pesticides, said U.S. farmers were unperturbed by lawsuits seeking damages from Bayer for an alleged cancer-causing effect of glyphosate-based herbicides.

Bayer says U.S. farmers unfazed by glyphosate litigation

Bayer faces a surge in lawsuits from people alleging that its weedkiller Roundup causes cancer, ratcheting up legal pressure company engages in settlement. 
The post Bayer Is Now Facing 42,700 Plaintiffs In Roundup Litigation appeared first on Investor's Business Daily.

Bayer Is Now Facing 42,700 Plaintiffs In Roundup Litigation

Germany's Bayer  said on Wednesday that the number of U.S. plaintiffs blaming its glyphosate-based weedkillers for their cancer mushroomed to 42,700 from 18,400 in July, raising the stakes in the group's efforts to reach a settlement.

Bayer says number of glyphosate plaintiffs jumps to 42,700

The lesson here is that smaller acquisitions may have a better chance of benefiting investors.

And the Winner for the Worst Corporate Deal is Bayer

Two Seattle-area startups were hand-picked by Bayer for a competitive program to create novel digital health solutions.

Bayer partners with Seattle startups Litesprite and Prevencio on digital health efforts

Bayer  expects the number of claims in the United States related to Roundup herbicide to have surged in the third quarter, as the German drugs and pesticides maker tries to reach a settlement after earlier court rulings against it.

Bayer expects significant surge in number of U.S. glyphosate cases

An Australian farmer has launched a legal action against Bayer AG’s agricultural chemicals unit Monsanto after being diagnosed with a type of cancer he claims was caused by its weedkiller, the Australian Broadcasting Commission reported on Thursday.

Australian farmer brings legal action vs Bayer over weedkiller: report

(This October 6 story has been refilled to correct "until February" to "until further notice" in headline and "new court date" to "court status conference" in paragraphs 1 & 6)

Bayer says Oct. U.S. glyphosate trial delayed until further notice

A pending U.S. lawsuit over claims related to Bayer's  glyphosate-based herbicide Roundup has been delayed, the company said on Sunday.

Bayer says another U.S. glyphosate trial is delayed

- Oerth Bio to utilize Arvinas’ PROTAC® technology to develop innovative new agricultural products to improve crop yields   - John Dombrosky Announced as CEO of Oerth Bio

Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio

Apple

Microsoft

Researchers are developing tools to help identify the probability of cardiovascular diseases, harnessing the power of artificial intelligence (AI).

Is Artificial Intelligence the Silver Bullet for Heart Disease?

Accenture Plc

The collaboration will benefit Accenture's (ACN) Life Sciences industry group, which is part of its Products segment.

Accenture's (ACN) INTIENT to Aid Bayer in Drug Development

Bayer  management board members Hartmut Klusik and Kemal Malik will leave at the end of the year without a replacement, as the German drugmaker reduces its board to five seats to cut costs.

Bayer to reduce size of management board to five

Bayer  said a law firm it had commissioned to investigate a compilation of data on journalists, politicians and researchers by Monsanto had found no evidence of illegal behavior by the seed maker that Bayer acquired last year.

Bayer says Monsanto's list of influential people was not illegal

Teva Pharmaceutical

One of the world’s largest and oldest pharmaceutical companies buys out one of the world’s largest agriculture firms, and the stock collapses in freefall.

Bayer, Teva Show Antitrust Law May Be Unnecessary

Bayer  said it hired Johnson & Johnson  executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline.

Bayer hires former J&J executive for more pharma deals

Bayer AG has recently initiated an organizational restructuring, divesting its animal health and chemical unit.

Bayer: Latest Shake-Up Could Change The Narrative

Bayer AG  is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement.

Explainer: What are the obstacles to Bayer settling Roundup lawsuits?

Elanco Animal Health Inc

Bayer (BAYRY) inks deal with Elanco to divest its animal health business for $7.6 billion.

Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco

On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.

Bayer Sells Animal Health Division to Elanco: Now What?

Elanco Animal Health Inc (NYSE: ELAN) shares were trading lower Tuesday after the company announced it would acquire Bayer AG (OTC: BAYRY)'s animal health business for $5.32 billion in cash and $2.28 billion in Elanco shares.

Elanco To Acquire Bayer's Animal Health Business For $7.6B

Elanco Animal Health  agreed to buy Bayer's  veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest animal health business and expanding Elanco's reach online.

News for Bayer AG Stock (BAYRY)